Mosapride treatment for functional dyspepsia: A meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 1, 2015, Pages 28-42

  Bang, Chang Seok ^a   Kim, Jong Hyeok ^a   Baik, Gwang Ho ^a   Kim, Hyo Sun ^a   Park, Sang Hyun ^a   Kim, Eun Jin ^a   Kim, Jin Bong ^a   Suk, Ki Tae ^a   Yoon, Jai Hoon ^a   Kim, Yeon Soo ^a   Kim, Dong Joon ^a  

^a Hallym University College of Medicine   (South Korea)

Author keywords

Functional dyspepsia; Meta analysis; Mosapride

Indexed keywords

MOSAPRIDE; PLACEBO; BENZAMIDE DERIVATIVE; GASTROINTESTINAL AGENT; MORPHOLINE DERIVATIVE; SEROTONIN AGONIST;

ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; DYSPEPSIA; FUNDING; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SCORING SYSTEM; SENSITIVITY ANALYSIS; THERAPY EFFECT; BIBLIOGRAPHIC DATABASE; META ANALYSIS; TREATMENT OUTCOME;

BENZAMIDES; DATABASES, BIBLIOGRAPHIC; DYSPEPSIA; GASTROINTESTINAL AGENTS; HUMANS; MORPHOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 84919628782     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12662     Document Type: Article

References (40)

1. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am. J. Gastroenterol. 2005; 100: 2324-2337.
2. Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis. 2006; 15: 237-241.
3. Tack J, Talley NJ, Camilleri M etal. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-1479.
4. Bisschops R, Karamanolis G, Arts J etal. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 2008; 57: 1495-1503.
5. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Do distinct dyspepsia subgroups exist in the community? A population-based study. Am. J. Gastroenterol. 2007; 102: 1983-1989.
6. Mizuta Y, Shikuwa S, Isomoto H etal. Recent insights into digestive motility in functional dyspepsia. J. Gastroenterol. 2006; 41: 1025-1040.
7. Makimoto N, Sakurai-Yamashita Y, Furuichi A etal. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytryptamine4 receptor in dog intestine. Jpn. J. Pharmacol. 2002; 90: 28-35.
8. Toga T, Kohmura Y, Kawatsu R. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J. Pharmacol. Sci. 2007; 105: 207-210.
9. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 1996; 17: 1-12.
10. Hallerback BI, Bommelaer G, Bredberg E etal. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment. Pharmacol. Ther. 2002; 16: 959-967.
11. Chen SY, Wang JY, Zhu CW etal. A randomized controlled multi-center clinical trial on mosapride in the treatment of functional dyspepsia. Chin. J. Epidemiol. 2004; 25: 165-168.
12. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment. Pharmacol. Ther. 2005; 21: 32-36.
13. Cooper HM. Synthesizing Research: A Guide for Literature Reviews. Thousand Oaks, CA: Sage, 1998.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-1558.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986; 7: 177-188.
17. Borenstein M, Hedges LV, Higgins J, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: Wiley, 2009; 77-86.
18. Olkin I. Statistical Methods for Meta-Analysis. San Diego, CA: Academic, 1985.
19. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
20. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Chichester, UK: Wiley, 2000.
21. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 2001; 54: 1046-1055.
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
23. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
24. Wu LF, Zheng ZM, Li GP etal. Effect of weishusan on patients with functional dyspepsia and H.pylori infection. World Chin. J. Digestol. 2002; 10: 275-278.
25. Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J. Indian Med. Assoc. 2004; 102: 735-737. 760.
26. Otaka M, Jin M, Odashima M etal. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment. Pharmacol. Ther. 2005; 21: 42-46.
27. Kinoshita Y, Hashimoto T, Kawamura A etal. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment. Pharmacol. Ther. 2005; 21: 37-41.
28. Lin J, Ren M, Peng X etal. Short-term efficacy of mosapride dispersible tablet on postprandial distress syndrome. Chin. J. Gastroenterol. 2009; 14: 488-490.
29. Kim YM, Park YC, Jo JH, Kang WC, Son MW, Hong KE. Effect of herb medicine treatment for functional dyspepsia: a randomized placebo-controlled and compared standard treatment trial. J. Korean Orient. Med. 2010; 31: 01-13.
30. Hsu YC, Liou JM, Yang TH etal. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J. Gastroenterol. 2011; 46: 183-190.
31. Liu B, Piao X, Guo L. Effect of herbal formula xiao pi-II on functional dyspepsia. J. Tradit. Chin. Med. 2013; 33: 298-302.
32. Hongo M, Harasawa S, Mine T etal. Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J. Gastroenterol. Hepatol. 2012; 27: 62-68.
33. Jiang Q, Ding X, Zhang S, Wang H, Yu X, Xie S. Comparison of mosapride and pantoprazole in treating functional dyspepsia. Chin. J. Gastroenterol. 2011; 16: 547-550.
34. Hiyama T, Yoshihara M, Matsuo K etal. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 2007; 22: 1566-1570.
35. Hiyama T, Yoshihara M, Matsuo K etal. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J. Gastroenterol. Hepatol. 2007; 22: 304-310.
36. Lacy BE, Talley NJ, Locke GR, 3rd etal. Review article: current treatment options and management of functional dyspepsia. Aliment. Pharmacol. Ther. 2012; 36: 3-15.
37. Karamanolis GP, Tack J. Current management of functional dyspepsia: impact of Rome III subdivision. Ann. Hepatol. 2012; 25: 96-99.
38. Mazzoleni LE, Sander GB, Francesconi CF etal. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch. Intern. Med. 2011; 171: 1929-1936.
39. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am. J. Gastroenterol. 2003; 98: 2621-2626.
40. Hartling L, Ospina M, Liang Y etal. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ 2009; 339: b4012.